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1. Abstract 
Background. Several reports have shown in patients with cystic fibrosis (CF) a significantly reduction of 
the levels of docosahexaenoic acid (DHA), which is involved in antioxydans response and in production 
of mediators identified as important factors during the resolution phase of inflammatory reaction. The 
deficit of DHA may play a role in the inflammatory cascade of pulmonary disease in CF patients.  
The aim of the study was: to determine the levels of the arachidonic acid (AA) metabolites and DHA in 
sputum of adults with CF subjects, as compared to patients with COPD; to ascertain whether or not 
DHA supplementation may affect the fatty acid pattern in CF subjects. 
Subjects & Methods. We studied 15 CF subjects and 10 COPD patients. CF patients (age range 20 to 
40) were recruited at the Cystic Fibrosis Unit of Parma Hospital and the control group of COPD patients 
were recruited at the University Hospitals of Modena-Reggio Emilia and Parma. At baseline all subjects 
performed: nutritional status evaluation, severity score evaluation (Shwachman-Kulczycki score), 
spirometry, exhaled NO measurement, exhaled breath condensate (EBC), sputum induction (SI) to 
evaluate leukotriene B4 (LTB4), prostaglandin E2 (PGE2), 15-hydroxyeicosatetraenoic acid (15-HETE), 
17-hydroxydocosahexaenoic acid (17OH-DHA), 15-HETE/17OH-DHA ratio,  and blood sample to 
evaluate DHA/AA ratio and HUFA index in the red cells (first phase). During the second phase, CF patients 
performed all evaluations after two weeks of systemic antibiotic therapy or/and after ten weeks with 
DHA-supplementation and after ten weeks without DHA-supplementation. 
Results. As compared to COPD patients, CF subjects showed increased concentrations of LTB4, PGE2, 
15-HETE. The concentrations of the DHA derived were not different in the two groups. 9 out of 15  CF 
patients (5 female) were clinically stable and completed second phase of the study. After ten weeks of DHA 
supplementation, CF subjects showed a tendency to decrease in LTB4 and PGE2 and to increase in 
17OH-DHA, and a significantly reduction in levels. At the end of the washout period, LTB4, PGE2, 15-
HETE, and  17OH-DHA tended to recover baseline values. After supplementation DHA/AA ratio and 
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HUFA index were significantly increased. As compared to baseline, 15-HETE/17OH-DHA ratio 
significantly changed  after supplementation. 
Conclusion. Our preliminary results showed that in CF patients an impairment in fatty acid metabolism, 
characterized by increase in AA metabolites and decrease in DHA, was partially corrected by DHA 
supplementation. A better understanding of these metabolic changes could provide new insights into 
disease pathophysiology and potentially could identify new biomarkers of disease severity.  
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2. Riassunto 
Razionale. Numerosi studi hanno documentato nella Fibrosi Cistica (FC) una significativa riduzione dei 
livelli di acido docosaexaenoico (DHA), coinvolto nella risposta antiossidante e nella generazione di 
metaboliti, quali resolvine e protectine, identificati come importanti fattori nella fase di risoluzione del 
processo infiammatorio. Tale deficit potrebbe pertanto svolgere un ruolo fondamentale nella  
progressione della cascata infiammatoria e della malattia polmonare.  
Scopo dello studio. In questa fase preliminare ci siamo proposti di: determinare il contenuto dei derivati 
dell’acido arachidonico (AA) e del DHA nell’escreato di soggetti adulti affetti da FC e verificare se la 
supplementazione con DHA sia in grado di migliorare il profilo degli acidi grassi. I risultati nei pazienti FC 
sono stati confrontati con quelli ottenuti in pazienti con bronco-pneumopatia cronica ostruttiva (BPCO). 
Materiali e Metodi. Lo studio ha coinvolto 15 soggetti affetti da FC reclutati presso la Struttura Semplice 
di Fibrosi Cistica dell’Azienda Ospedaliera Universitaria di Parma e 10 soggetti affetti da BPCO reclutati 
presso la Clinica Pneumologica dell’Università di Parma e di Modena-Reggio Emilia. Il protocollo dello 
studio è articolato in due fasi. Nella prima fase sono stati valutati nell’escreato i mediatori leucotriene B4 
(LTB4), prostaglandina E2 (PGE2), acido 15-idrossieicosatetraenoico (15-HETE), acido 17-
idrossidocoexainoico (17OH-DHA), il rapporto 15-HETE/17OH-DHA e negli eritrociti il rapporto 
DHA/AA e l’indice degli acidi grassi polinsaturi n-3 (HUFA index). Nella seconda fase sono state valutate 
le variazioni dei medesimi mediatori dopo due settimane di trattamento con antibioticoterapia ev e/o 
dopo dieci settimane di supplementazione di DHA nella dieta alla dose di 3 g/die e dopo dieci settimane 
senza supplementazione.  
Risultati. L’esame citologico dell’escreato in condizioni basali ha dimostrato la presenza di una 
infiammazione di tipo neutrofilico in tutti i pazienti FC. Rispetto ai soggetti BPCO, i pazienti affetti da FC 
presentano una aumentata concentrazione di LTB4, PGE2 e 15-HETE. Non sono emerse differenze tra i 
due gruppi per la concentrazione del 17OH-DHA. 9/15 pazienti FC (5 donne) erano in fase di stabilità 
clinica e hanno ripetuto la valutazione nutrizionale e funzionale e dei mediatori lipidici dopo dieci 
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settimane di supplementazione di DHA nella dieta e dopo dieci settimane senza supplementazione. Dopo 
dieci settimane di supplementazione con DHA nei soggetti FC abbiamo osservato nello sputo una 
riduzione (X ±DS) di LTB4, PGE2 e 15-HETE, che per quest’ultimo raggiunge la significatività statistica. 
Al contrario, il  17OH-DHA aumenta alla fine della supplementazione. Al termine del periodo di wash-
out, LTB4, PGE2 e 15-HETE aumentano senza raggiungere i valori basali; mentre il 17OH-DHA è 
sostanzialmente invariato. Inoltre, dopo la supplementazione, l’analisi di composizione degli acidi grassi 
negli eritrociti ha evidenziato un aumento statisticamente significativo del rapporto DHA/AA e 
dell’HUFA index. Inoltre, dopo la supplementazione con DHA, il rapporto 15-HETE/17OH-DHA si 
riduce in modo statisticamente significativo rispetto al basale. 
Conclusioni. Questi risultati preliminari dimostrano che nei soggetti FC esiste uno squilibrio del 
metabolismo degli acidi grassi con aumento dei mediatori derivati dall’AA e riduzione dei derivati del 
DHA, parzialmente corretto dalla supplementazione dietetica con DHA. La conoscenza dettagliata di 
queste alterazioni metaboliche potrebbe contribuire a sviluppare specifiche terapie personalizzate sul 
profilo infiammatorio di ogni paziente. 
7 
 
3. Introduction 
More than eight decades have passed since the first description of Cystic Fibrosis (CF) as a deadly 
childhood disease of the pancreas. Since then, it has been recognized as one of the most common fatal 
recessive diseases among white persons, usually diagnosed during the first years of life and characterized 
primarily by pulmonary and gastrointestinal symptoms. 
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CF in the history 
A documented history of CF did not exist until well into the 1930s. Many cases back then of what could 
have been CF were misdiagnosed as whooping cough, chronic bronchitis or pneumonia. However, there 
has been a feeling of consciousness of what CF is since the 1700s, as popularized by the German saying, 
“A child whose forehead tastes like salt when kissed will soon die.”  
The 1930s can be said to be the period of discovery for CF. What is considered to be the earliest paper 
written on the disease was made by Swiss pediatrician Dr. Fanconi. The doctor called the illness “celiac 
syndrome,” which he defined as changes in the pancreas as observed in children [1]. The term Cystic 
Fibrosis was coined by Dr. Dorothy Andersen of Babies’ Hospital New York. She also theorized that the 
condition is caused by deficiency in Vitamin A [2]. Changing theories on the nature of cystic fibrosis 
marked this decade’s history. Drs. Sidney Farber and Harry Shwachman connected the abnormal secretion 
of mucus to the disease [3]. The idea that Vitamin A is the underlying cause of CF was challenged by a 
number of researchers, including Dr. Anderson, the person who proposed it in the first place. In 1949, 
Lowe et al. postulated that CF must be caused by a defect in a single gene (and therefore a single protein) 
on the basis of the autosomal recessive pattern of inheritance of the disease [4]. 
The 1950s saw the beginnings of the sweat test, the standard test now used for diagnosing CF. The test 
was developed as a result of discoveries made by Dr. Paul di Sant’Agnese during the heat wave in New 
York in 1950 [5]. In 1955, Dr. Shwachman laid the foundation for the modern way of treating CF, which 
was early diagnosis, active early treatment and proper nutrition. Moreover, Dr. Archie Norman began 
studies on high fat diets for treating the disease in London that year [6].  
The 1960s is the period when organizations specializing in CF research were formed. These organizations 
were initiated by parents of children afflicted with the disease, as well as rare patients who lived long 
enough to see adulthood.  
Preliminary work on proper neonatal screenings for diagnosis was the hallmark of the 1970s. This was 
also the decade that saw the developing of many more specialized clinics for CF, as well as the advocacy 
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for high-fat diets to treat the condition [7]. The Cystic Fibrosis Foundation in the United States also 
pioneered the use of the patient registry during this decade.  
Further advancements in treating the disease occurred during the 1980s. It was during this decade that the 
greatest finding on the disease, none other than the discovery of the Cystic Fibrosis Transmembrane 
Conductance Regulator (CFTR) gene, was made (this was in 1989) [8]. Use of gene replacement therapies 
began as part of the treatment for cystic fibrosis. Peter Durie and others in the 1980’s demonstrated that 
the CF pancreas has both chloride and bicarbonate secretion defects [9]. Also, the Food and Drug 
Administration approved the use of the mucolytic pulmozyne, the first drug designed to target CF. 
The total number of patients with CF worldwide is not known, but approximately 30,000 patients are 
listed in the cystic fibrosis registry in the United States [10]. The median life expectancy of patients with 
cystic fibrosis is on the rise and has changed dramatically, within a period of three decades, from 
approximately 10 years to approximately 38 years. This favorable result has been  achieved through 
research; through the development of adequate medications, especially enteric-coated pancreatic enzymes; 
through the use of prophylactic medications; through treatment by multidisciplinary CF teams; and 
through early intervention for patients who have pulmonary exacerbations. 
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CF Epidemiology 
CF is a chronic, progressive, and frequently fatal autosomal recessive disorder caused by mutations in the 
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. Heterozygous carriers (those who 
have inherited only one copy of the altered gene) are asymptomatic. Its estimated heterozygote frequency 
in white people is up to 1 in 20. Each offspring of 2 heterozygote parents has a 25% chance of developing 
cystic fibrosis. The worldwide incidence varies from 1 case per 377 in England to 1 case per 90,000 in 
Hawaii. In the United States, the prevalence is as follows: 
 Whites of northern European origin - 1 case per 3,200-3,500 population; 
 Hispanics - 1 case per 9,200-9,500 population; 
 African Americans - 1 case per 15,000-17,000 population; 
 Asian Americans - 1 case per 31,000 population [10]. 
The disease occurs mostly in Caucasian population, although it affects all races and ethnic groups. 
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CF Pathogenesis 
CF is caused by mutations in CFTR, an apical membrane anion channel involved in epithelial fluid 
secretion and salt absorption [11]. The most important aspects of CF’s pathophysiology arise from 
alterations in extracellular fluids, such as, premature activation of pancreatic enzymes, increased viscosity 
of mucus and consequent ductal blockage and irritation.  
CFTR gene 
CFTR gene, which is responsible for this disorder, encompasses approximately 180,000 base pairs, it 
contains 27 exons spreading over 250 kb of chromosome 7 (7q31) and it encodes an mRNA of 6.5 kb. 
The most common mutation is termed ΔF508 and it's present in approximately 70% of defective CFTR 
alleles and in 90% of patients with CF in the United States [12]. In Europe, there exists a great 
heterogeneity in the spread of CF, there is a north-west/south-east gradient (i.e. 88% of ΔF508 cases 
found in Denmark and 50% in Italy). To explain the spread of this mutation in European population, the 
hypothesis of a selective advantage of heterozygotes was proposed [12]. Since the discovery of CFTR 
gene, more than 1200 mutations are described since the duplicating of this gene, out of which 4 (excluding 
ΔF508) represent more than 2%. The frequency of certain mutations can vary among different geographic 
groups: as result of a genetic founder effect, W1282X mutation is particularly prevalent among persons of 
Ashkenazi Jewish descent (48% of CF alleles among the Ashkenazi Jews and only 2% of the total CF 
alleles) [12].  
All types of mutations are represented (missense, frameshift, nonsense, splice, small and large in-frame 
deletions or insertions), and are distributed throughout the entire gene. The potential of a mutation to 
contribute to the severity of a CF phenotype depends on multiple factors. The majority of molecular 
defects of CFTR gene are the point mutations out of which 42% are missense mutations, 24% small 
insertions/deletions with a frame shift, 16% nonsense mutations, 16% mutations of splicing and 2% 
deletion of an amino acid. One of the particularities of CFTR gene is the existence of deleted transcripts 
of one or more exons among normal individuals. These transcripts are due to anomalies leading to 
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alternative splicing, out of which the most frequent and well-studied is the deleted transcript of exon 9 (9-
). The presence or absence of this exon is correlated with a "polymorphism" of sequence of the intron 8 
situated near the acceptor site of splicing [13].   
Various mutations can be grouped into different classes based on their known or predicted molecular 
mechanisms of dysfunction and functional consequences for the CFTR protein. The classification, which 
was first proposed by Tsui [14], has subsequently been expanded and refined to accommodate more data 
[15]. Although schematic, such classification can often be a good indication of a mutation’s severity and 
provides a rationale for their phenotypic consequences (Tab. 1). In fact, individuals with class I, II and III 
mutations, on average, have shortened survival compared with those who have “mild” genotypes (class 
IV, V and VI). The clinical importance of these functional categories is limited because they do not 
uniformly correlate with specific clinical features or their severity [15].   
ΔF508 is a 3-bp deletion in exon 10 causing a loss of phenylalanine at the amino acid position 508 of the 
protein product and it is categorized as a class II defect. The defective protein retains substantial chloride-
channel function in cell-free lipid membranes. When synthesized by the normal cellular machinery, 
however, the protein is rapidly recognized as misfolded and is degraded shortly after synthesis, before it 
can reach its crucial site of action at the cell surface. Like ΔF508, several other clinically important 
mutations — such as N1303K, G85E, and G91R — lead to misfolded CFTR protein that is prematurely 
degraded [13]. 
About 5% to 10% of CFTR mutations are due to premature truncation or nonsense alleles (designated by 
“X,” such as G542X, a class I mutation). Other CFTR mutations encode properly processed, full-length 
CFTR protein that lacks normal ion-channel activity. For example, the G551D mutation (class III) is 
believed to possess little or no chloride-channel function in vivo because of abnormal function of a 
nucleotide-binding domain, resulting in disordered regulation. The A455E mutation (class IV) exhibits 
only partial CFTR ion-channel activity, a feature that probably explains a less severe pulmonary 
phenotype. Other mutation classes include reduced numbers of CFTR transcripts (class V) and defective 
CFTR stability at the cell surface (class VI) [13]. 
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Table 1: classification of CFTR molecular anomalies and its effects on the CFTR protein morphology and 
functions [15] 
Mutation Class Type of Mutation Effects on Protein Example 
Class I 
This class includes the nonsense mutations and 
those that produce a premature stop codon 
(anomalies of splicing and frameshift mutations). In 
certain cases the mutated mRNA is unstable and 
doesn’t produce the protein. In other cases, the 
abnormal protein produced will probably be 
unstable and degrade rapidly. 
Defective Protein Synthesis (Net Effect: No 
CFTR Protein at the Apical Membrane) 
G542X 
Class II 
A number of mutations alter the maturation of the 
protein and thus the transport of these proteins to 
the plasma membrane. 
Abnormal Processing and Trafficking (Net 
Effect: No CFTR Protein at the Apical 
Membrane) 
ΔF508 
Class III 
These mutations are frequently situated in the ATP 
binding domain (NBF1 and 2) and disturbing the 
regulation of Cl- channel.   
Defective Regulation (Net Effect: Normal 
Amount of Nonfunctional CFTR at the 
Apical Membrane). 
G551D 
Class IV 
Certain segments of membrane spanning domains 
participate in the formation of an ionic pore. The 
missense mutations situated in these regions 
produce a correctly positioned protein that has a 
cAMP dependant Cl- channel activity. 
Decreased Conductance (Net Effect: Normal 
Amount of CFTR with Some Residual 
Function at the Apical Membrane) 
R117H, 
R334W, 
R347P 
Class V 
Various mutations may be associated with reduced 
biosynthesis of fully active CFTR due to partially 
aberrant splicing (3849+10kbC→T), promoter 
mutations or inefficient trafficking. 
Reduced Synthesis/Trafficking (Net Effect: 
Reduced Amount of Functional CFTR at the 
Apical Membrane) 
A455E 
Class VI 
Truncation of the C-terminus of CFTR leads to the 
marked instability of an otherwise fully processed 
and functional variant. These are usually nonsense 
or frameshift mutations causing a 70- to 100-bp 
truncation of the C-terminus of the CFTR. 
Decreased Stability (Net Effect: Functional 
but Unstable CFTR Present at the Apical 
Membrane). 
Q1412X, 
4326delTC, 
4279insA 
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CFTR protein 
The CFTR gene encodes a transmembrane protein with a symmetrical, multi-domain structure, consisting 
of two membrane-spanning domains, two nucleotide-binding domains and a central, highly charged 
regulatory domain (R) with multiple phosphorylation consensus sites. The principal function of CFTR is 
that of chloride transport at the apical membranes of epithelial cells but it has also been implicated in 
many other processes such as regulation of other ion channels, membrane trafficking, pH regulation and 
apoptosis. 
CFTR is synthesized and assembled in the endoplasmic reticulum (ER). During the earliest steps of this 
process, nascent chain-ribosome complexes are targeted to the ER membrane, and transmembrane 
segments are precisely oriented and integrated into the lipid bilayer [16]. Additional biogenesis events 
involve the packing of transmembrane helices, folding of cytosolic domains, and finally, assembly of these 
domains into a mature tertiary structure [17]. This process is mediated by specialized cellular machinery 
that includes the Sec61 translocation complex and cytosolic (hsp70, hsp40) as well as ER (calnexin) 
chaperones that assist folding and prevent aggregation of folding intermediates [18]. CFTR maturation is 
thus a stepwise and compartmentalized process that coordinates folding of different protein domains in 
the lipid environment of the ER membrane, the oxidizing environment of the ER lumen and the reducing 
environment of the cytosol. 
CFTR is the only known anion channel that links an enzymatic activity (adenosine triphosphate (ATP) 
hydrolysis) to opening and closing of the pore (channel gating). CFTR owes this property to its origin as 
an ATP-binding cassette transporters (ABC transporter), many others of which are active transport 
ATPases or pumps [19].  
ABC-transporter are members of a protein superfamily that is one of the largest and most ancient families 
with representatives in all existent phyla from prokaryotes to humans. ABC proteins were known to 
function as mediators of organic solute transport and included, for example, the genes that encode 
multidrug resistance (i.e., MDRs, or P-glycoprotein genes), a gene that encodes chloroquine resistance in 
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Plasmodium falciparum, and a number of prokaryotic and eukaryotic small nutrient and molecular 
transporters [20]. ABC transporters are transmembrane proteins that utilize the energy of ATP hydrolysis 
to carry out certain biological processes including translocation of various substrates across membranes 
and non-transport-related processes such as translation of RNA and DNA repair. They transport a wide 
variety of substrates across extra- and intracellular membranes, including metabolic products, lipids and 
sterols, and drugs [19]. Proteins are classified as ABC transporters based on the sequence and organization 
of their ABC domain(s). The common feature of all ABC transporters is that they consist of two distinct 
domains, the transmembrane domain (TMD) and the nucleotide-binding domain (NBD). The TMD, also 
known as membrane-spanning domain (MSD) or integral membrane (IM) domain, consists of alpha 
helices, inserted in the membrane bilayer. It recognizes a variety of substrates and undergoes 
conformational changes to transport the substrate across the membrane [19]. The NBD or ATP-binding 
cassette (ABC) domain, on the other hand, is located in the cytoplasm and it has a highly conserved 
sequence. The NBD is the site for ATP binding. The structural architecture of ABC transporters consists 
minimally of two TMDs and two ABCs. Two ATP molecules bind in pockets at the interface of an NBD 
dimer; each binding pocket is lined with residues from both NBDs. ATP binding to both sites creates or 
stabilizes the NBD dimer with an associated rearrangement of the translocation pathway by a proposed 
tweezer-like mechanism. For an exporter, this involves a shift from an inward-facing conformation with 
high substrate affinity to an outward conformation with low substrate affinity. Long cytosolic loops 
connect the NBDs to the TMDs and mediate the coupling between ATP binding and structural 
rearrangements of the TMDs. The transporter is reset to the inward-facing conformation following ATP 
hydrolysis at one or both sites [21].  
Like this generic ABC transporter, CFTR also possesses two TMDs and two NBDs, binds two ATP 
molecules at the interface of an apparent NBD dimer, and exhibits ATPase activity, even if predominately 
at one site [21]. Channel opening is normally associated with ATP binding at both composite sites, which 
promotes or stabilizes an NBD1-NBD2 dimer that can be detected functionally or biochemically by 
cysteine cross-linking. What makes CFTR different from typical ligand-gated channels is the exceptionally 
slow rate of ATP unbinding (koff < 0.2 s-1), which is due presumably to the tightness of the NBD1-
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NBD2 dimer. This is where the enzymatic activity of CFTR comes in; ATP hydrolysis and subsequent 
product release destabilize the dimer and increase the probability of channel closure [22]. 
Numerous laboratories have now established that CFTR conducts chloride across the cell membrane. It 
down-regulates transepithelial sodium transport, in particular the epithelial sodium channel; it also 
regulates calcium-activated chloride channels and potassium channels and may serve important functions 
in exocytosis and the formation of molecular complexes in the plasma membrane [23].
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Clinical manifestations 
Mutational heterogeneity and environmental factors appear responsible for highly variable involvement of 
the lungs, pancreas, and other organs. A list of presenting manifestations is overlong, although pulmonary 
and gastrointestinal presentation predominant (Table 2). 
Respiratory tract  
Chronic infection in CF is limited to the airways. In human lung, dense, tenacious secretions obstruct the 
distal airways and submucosal glands, which express CFTR [24]. Ductular dilatation of these glands 
(associated with obstruction by mucus) and the plastering of airway surfaces by viscous, neutrophil-
dominated mucopurulent debris are among the pathological hallmarks of the disease. Glandular 
hyperplasia in submucosal regions is prominent and enclosed by peribronchiolar inflammation with scar 
tissue. Submucosal gland ducts are inconspicuous in lungs of patients without CF, whereas luminal 
dilatation by mucus is one of the earliest visible changes in lungs of CF children. Pathogens such as 
Pseudomonas aeruginosa, Burkholderia cepacia, Staphylococcus aureus, and Haemophilus influenza become well 
established within firmly fixed airway secretions in patients affected and are not effectively eradicated. P. 
aeruginosa, specifically adapts to the pulmonary microenvironment in CF patients through the formation of 
biofilms and the production of a capsular polysaccharide (an alginate product) that inhibits penetration by 
antipathobiologic microbial agents and confers the mucoid phenotype [25]. 
Pulmonary inflammation is another important cause of the decline in respiratory function in CF patients 
and may precede the onset of chronic infection. Elevated levels of interleukin-8 (IL-8), interleukin-6 (IL-
6), tumor necrosis factor α (TNF-α), and leukotriene B4 (LTB-4), along with reduced levels of anti-
inflammatory cytokines and proteases, have been found in the airways of patients affected. Toll-like 
receptors (TLR), which recognize a variety of inflammatory mediators (i.e. neutrophil elastase, bacterial 
lipopolysaccharide, and other microbial products), partially mediate inflammatory effects by activating the 
transcription factor nuclear factor- кB (TFN-кB), which governs a molecular pathway that induces the 
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production of inflammatory mediators and cytokines [26]. These and other inflammatory molecules (such 
as mannose-binding protein and α1–antitrypsin) influence the progression of respiratory disease [27]. 
Recently, an elevated ratio of arachidonic acid (AA) to docosahexaenoic acid (DHA) was found in 
mucosal scrapings from CF patients, as compared to scrapings from normal peaple and from patients with 
inflammatory bowel disease; thus, the altered ratio cannot be explained by systemic inflammation alone 
[28]. 
Cough is the most important symptom of pulmonary involvement. At first, the cough may be dry and 
hacking, but eventually it becomes movable and productive. In adults, the cough is most prominent on 
arising in the morning or after sporting activity. Expectorated mucus is often purulent. Some patients 
remain asymptomatic  for long time or seem to have prolonged but intermittent acute lung infections. 
Other acquire a chronic cough in the first weeks of life, or they have pneumonias repetitively. Extensive 
bronchiolitis is attended by wheezing, which is a frequent symptom during the first years of life. 
Exacerbations of lung symptoms, presumably owing to more active airways infection and bronchiectasis, 
eventually require repeated hospitalizations for intravenous antibiotic treatment. Cor pulmonale, acute 
respiratory failure and death eventually occur unless lung transplantation is accomplished [29]. 
Spirometry has long been the accepted standard in disease follow up. Forced expiratory maneuvers such 
as forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) are well 
understood, and almost universally FEV1 is used to define mild (60% - 70% of predicted), moderate, and 
severe (40% - 30%) disease. Although the coefficient of variability for FEV1 in normal people is reported 
to be around 2–3% [30], it is much higher in CF patients [31]. Flows at lower lung volumes (i.e., the 
forced expiratory flow during the middle half of the forced expiratory maneuver [FEF25%-75%]), which 
may reflect obstruction of small airways, is the site of interest. The measurements are extremely technique 
and effort dependent. Some patients find such maneuvers difficult, and they are not routinely performed 
in 5 years old young children. The measurements also lack sensitivity, particularly in mild, early stages of 
disease or when looking for small changes in response to an intervention, and there is currently a very 
slow rate of decline (1–2% per year) in the CF population [32]. This means that, though patients who are 
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deteriorating rapidly or over a short time period can be easily identified, observing any improvement on 
this rate of decline in an individual patient will be difficult. Finally, although FEV1 has historically been 
used in defining severity, there is some evidence to suggest it is not a very useful tool on which to base 
prognosis. In fact, FEV1 is no longer included in the lung allocation score as part of transplant-waiting-list 
assessment in the United States [33]. 
Lung volumes (measured with pletismography) and diffusion capacity are listed in some of the current 
consensus documents for annual assessment, and are performed in the majority of modern centers, at 
least in Europe. Similarly to spirometry, they require cooperation and recent data suggest that lung-volume 
values add very little to spirometry for the majority of CF patients [34]. 
The Lung Clearance Index (LCI) uses multiple-breath wash-out of a non-absorbable gas (nitrogen and, 
more commonly now, sulfur hexafluoride) to measure ventilation inhomogeneity owing to airway 
narrowing from inflammation or mucus obstruction. The patient inhales a low concentration of sulfur 
hexafluoride, via either mask, until the concentration in the airways is in equilibrium with the 
concentration administered (wash-in phase). The supply is then switched off and, during continued tidal 
breathing, wash-out is monitored. Gas analyzers include conventional mass spectrometer or photoacoustic 
and ultrasonic-based technologies. Wash-out is defined as the point when the sulfur hexafluoride reaches 
1/40th of its original concentration. Patients with more severe disease take longer to wash out phase, 
because gas is trapped in airways; therefore, they have a higher LCI. One advantage of the LCI is that it 
has a quite narrow range of normal values, which obviates the requirement for age/size-adjusted normal 
values [35]. The technique is easy to perform (requires only tidal breathing, and no additional 
coordination, cooperation, or forced maneuvers) and it can be performed at all ages (including infancy and 
pre-school ages); it is repeatable, reproducible, and more sensitive at the early stages of disease than 
spirometry [36-38].Finally, it is as sensitive as forced expiratory maneuvers in infants and correlates better 
with structural changes on high-resolution computed tomography (HRCT) than does FEV1 [39]. An 
important disadvantage of the LCI is that completely obstructed lung regions do not contribute to the 
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overall measurement because the inhaled gas does not spread those regions. In CF patients who have 
totally obstructed lung regions, the LCI could underestimate respiratory disease severity [40].  
CF sputum contains high levels of inflammatory cells, pro-inflammatory cytokines, and proteolytic 
enzymes; some of these appear to correlate with other measurements of pulmonary involvement, such as 
spirometry, although whether they cause the pulmonary damage is less clear. Cytokines can be measured 
reproducibly, even in sputum from young children, and numerous of these are reduced by treatment with 
conventional intravenous antibiotics and other treatments [41-42]. A study that found changes in sputum 
cytokines after nebulized heparin found no corresponding changes in spirometry, which may suggest 
either that this technique is more sensitive to detect change than conventional lung function, or may 
simply reflect the fact that changes in lung function may occur in advanced disease [43]. Promisingly, 
results suggest that spontaneous sputum and samples obtained via induction methods based on 
nebulization of hypertonic saline are not significantly different with respect to inflammatory markers [44]. 
Interpreting these data is rather problematic, due to the varied and often unvalidated methods used in the 
processing stage. For example, mucolytics such as dithiothreitol are often used. Dithiothreitol, by cleaving 
disulphide bonds, affects the levels of proteins and may adversely affects reagents in the assay system [45]. 
A second concern relates to the lack of standardization of nature and concentration of protease inhibitors 
used. Both of these issues may be specific to the type of assay used and the substance measured. There is 
an urgent need to address these methodological issues, specifically for CF sputum, before this test can be 
routinely used within the clinical context. 
Much interest has focused on the observation that the level of exhaled NO (FeNO) is reduced in CF. 
Given the anti-inflammatory and anti-infective properties of NO, some think it may play an important 
primary role in CF pathophysiology—a hypothesis supported by the low level of NO synthase messenger 
ribonucleic acid in relatively undamaged airways [46]. An alternative view is that NO production is itself 
adversely affected by inflammation and that low NO level is secondary to CF lung disease. NO level is 
extremely low in primary ciliary dyskinesia, a disease with a generally much better outlook than CF. A 
recent clinical trial of orally administered L-arginine (an NO donor) with CF subjects used exhaled NO as 
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an outcome and reported a sustained increase in NO production, although this was not mirrored by any 
significant effect on lung function [47]. However, no studies have addressed longitudinal change or 
correlations with other clinical variables, which would support this measure as a useful monitoring tool in 
the clinic. 
Exhaled Condensate can be collected simply by asking a patient, even a quite young child, to exhale into a 
cold tube during tidal breathing. The condensate contains a small (but variable and undetermined) volume 
of airway-lining fluid, the pH of which is peculiarly low in CF [48]. However, this technique appears to 
lack sufficient sensitivity for use with an individual subject [49, 50]. 
Intestinal and biliary tract 
Pancreatic insufficiency is the most frequent gastrointestinal manifestation in CF. More than 85% of 
affected patients show evidence of maldigestion from exocrine pancreatic insufficiency. Symptoms include 
recurrent, bulky, greasy stools and failure to gain weight even when food intake appears to be large. Nearly 
40% of patients display nutritional failure by the criterion of weigh/height less than the 10th percentile 
[51]. Characteristically, stools contain readily visible droplets of fat. A protuberant abdomen, decreased 
muscle mass, poor growth, and delayed maturation are typical physical signs. The diagnosis of pancreatic 
insufficiency is a clinical one. The most effective test to confirm the diagnosis is to measure faecal elastase, 
which is low in people with pancreatic insufficiency [53]:  
 Normal >200 mcg/g stool; 
 Mild/moderate pancreatic insufficiency 100-200 mcg/g stool; 
 Severe pancreatic insufficiency <100 mcg/g stool; 
 CF pancreatic insufficiency <15 mcg/g stool. 
This is not affected if children are already taking pancreatic enzymes. In patients who have residual 
exocrine pancreatic function, recurrent acute pancreatitis occurs occasionally. In addition to exocrine 
pancreatic insufficiency, evidence for hyperglycemia, polyuria, glycosuria and weight loss may appear. 
22 
 
Moreover, 8% of 11-17 years old patients and 18% of 18-24 years old patients have insulin-dipendent 
diabetes [54]. 
Meconium ileus (MI) at birth, distal intestinal obstruction syndrome (DIOS, formerly designated 
“meconium ileus equivalent”), and constipation are all consequences of the increased viscosity of 
intestinal mucus and the prolonged intestinal transit time in CF [55]. 
In 13-17% of newborn infants with CF, the ileum is completely obstructed by meconium. MI is unique to 
CF and is clearly influenced by genetic factors, because a large twin study reports that homozygous twins 
show a greater concordance for MI than heterozygous twins [56]. Abdominal distension, emesis, and 
failure at pass meconium appear in the first 24-48 hours of life. Abdominal radiographs show dilated 
loops of bowel with air-fluid levels and, frequently, a collection of “ground glass” material in the lower 
central abdomen. Rarely, meconium peritonitis results from intrauterine rupture of the bowel wall and can 
be detected radiographically by the presence of peritoneal or scrotal calcifications. Meconium plug 
syndrome occurs with increased frequency in infants with CF but is less specific than MI [55]. 
Survival in patients with MI has improved dramatically; some authors report that survival through the first 
year of life increased from 55% in CF patients born between 1958 and 1972 to 96% in those born 
between 1973 and 1987 [57]. More recent articles even report no differences in survival between MI and 
non-MI patients [58, 59] In contrast, the long-term outcome of pulmonary function in MI patients is less 
uniform between the MI and non-MI groups. Some studies suggest that MI patients have a worse 
pulmonary phenotype, when corrections for the advantage of early detection and treatment were made 
[60, 61]. 
After the neonatal period, DIOS emerges, characterized by complete or incomplete intestinal obstruction 
of viscid fecal accumulation in the terminal ileum and proximal colon [55]. Characteristically, DIOS 
patients have abdominal pain, distension, and vomiting in combination with a right lower quadrant mass, 
which is palpable and usually seen on plain abdominal radiography. An important differential diagnosis of 
DIOS is constipation. However, in contrast to DIOS, symptoms are usually milder and have longer 
standing. Each condition is frequently seen in CF patients, with constipation in particular being greatly 
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underdiagnosed in CF [62]. The incidence (2.2–6.2 episodes per 1000 patient-years) and lifetime 
prevalence (7–8%) of DIOS in childhood is low [63]. Two studies report that DIOS incidence and 
lifetime prevalence increase as patients become older [64, 65]; indeed, incidence (23.3 episodes per 1000 
patient-years) and lifetime prevalence (14–16%) are higher in adult patients. Additionally, DIOS is 
recurrent medical issue, because 20% of all pediatric patients experienced more than one episode during a 
5-year observation period [64, 65]. Some studies report an increased frequency of severe CFTR genotypes 
in DIOS [63], whereas others report no differences [64], and a large twin study shows equally low 
concordance rates for DIOS in heterozygous and homozygous twins [66]. After lung transplantation, 
DIOS is frequently seen; about 10% to 20% of CF lung transplant patients develop at least one DIOS 
episode early in the post-transplant period [67]. The transplantation period is characterized by 
dehydration, immobility, and opiate use; all of these could promote fecal impaction in the ileo-cecum, 
eventually leading to complete intestinal obstruction in selected patients. Therefore, starting preventive 
laxative treatment in these high-risk patients after lung transplantation could be considered. Most DIOS 
episodes can be treated conservatively with intensive laxative treatment (oral laxatives and/or enema or 
polyethylene glycol lavage), and most large studies report low numbers of surgical interventions [62]. 
Less frequent gastrointestinal manifestation include intussusception, fecal impaction of the cecum with an 
asymptomatic abdominal mass, and duodenal inflammation with epigastric pain. In adults, acid or bile 
reflux with esophagitis symptoms is common. Rectal prolapse occurs much less frequently as the result of 
earlier diagnosis of pancreatic insufficiency and initiation of pancreatic enzyme replacement treatment.  
Clinical manifestations of fat-soluble vitamin deficiencies have been noted: 
 neurologic dysfunction (dementia, peripheral neuropathy) and hemolytic anemia owing to 
vitamin E deficiency;  
 bleeding diathesis and hypoprothrombinemia owing to vitamin K deficiency;  
 decreased bone density and rickets (rarely) owing to vitamin D deficiency; 
 night blindness owing to vitamin A deficiency. 
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Manifestation of biliary tract involvement can include icterus, ascites, hematemesis from esophageal 
varices, and evidence of hypersplenism. Liver disease occurs independent of genotype but is associated 
with MI and pancreatic insufficiency. Evidence for liver dysfunction is most often detected during the first 
15 years of life (> 30% of CF patients). Biliary colic secondary to cholelithiasis may occur in the second 
decade or later. A neonatal hepatisis-like picture and massive hepatomegaly owing to steatosis have been 
documented [68].  
Genitourinary tract 
Sexual development is often delayed and adolescent females may experience secondary amenorrhea, 
especially during respiratory exacerbations. The female fertility rate is diminished, owing to frequent 
cervicitis and accumulation of tenacious mucus in the cervical canal. Pregnancy is generally well tolerated 
in patients with good pulmonary function; on the contrary, pregnancy may accelerate pulmonary 
progression in those with advanced lung involvement [69]. 
More than 95% of males suffer from bilateral absence of the vas deferens and other forms of obstructive 
azoospermia, because of failure of development of Wolffian duct structures. The incidence of inguinal 
hernia, hydrocele, and undescended testis is higher than general population [70]. 
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Genotype and Phenotype in CF 
Studies of clinical phenotype in CF in correlation with CFTR genotype have discovered a very complex 
relationship. A CFTR genotype is only a predisposition for CF disease, which will be expressed to various 
penetrance and translated into CF pathophysiology. The content of the ‘black box’ linking genotype and 
clinical outcome is slowly being unraveled by a growing number of studies examining CFTR defects, by 
evaluating their molecular and cellular effects and ultimately relating them to a clinical phenotype [13]. In 
fact, of more than 850 mutations reported to the CF Consortium, a small part have been evaluated at the 
transcript or protein level and some of them have also been tested for their functional effects [12]. 
The extent by which CF phenotype is determined by specific CFTR mutations varies significantly from 
organ to organ. 
Pulmonary involvement 
There was considerable variation in severity of pulmonary disease in CF, even within patients belonging to 
the same genotype group. Among studies using more sophisticated assessment of CFTR mutations, such 
as those classifying their molecular mechanisms, or extent of the CFTR chloride channel function, some 
have shown statistically significant correlations between CFTR genotypes and pulmonary status [71, 72] 
while others have failed to detect a significant association [73, 74].  
However, an important longitudinal study demonstrated a significant difference in the rate of decline of 
pulmonary function between patients with pancreatic sufficiency and pancreatic insufficiency mutations 
[75]. Pancreatic sufficiency phenotype is predominantly associated with mild CFTR mutations, which 
retain some residual chloride channel activity. The strongest association between mild pulmonary disease 
and a specific CFTR mutation was found for the missense allele A455E [76]. When this mutant variant 
was expressed in a heterologous cell system, slightly reduced Cl currents were identified with normal 
conductance and gating properties. However, its presence in the apical membrane was significantly 
reduced, with incomplete processing and degradation [77]. Of interest, in vivo studies showed no 
correction of the bioelectric properties in nasal epithelial cells of patients with this mutation [78]. If the 
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same is valid for lower airways, other mechanisms may exist for lightening the pulmonary involvement in 
patients with this genotype. There may be other specific mutations consistently associated with a mild lung 
presentation, like the G551S allele, but the minor number of patients analyzed do not consent for a 
definite conclusion [79, 80]. 
Other studies suggest that early respiratory outcome in CF children may depend on specific CFTR 
mutations progression of pulmonary disease. Poor or no genotype correlations in more advanced stages of 
CF lung involvement may be due to an influence of modifying factors in the later phase of the disease (i.e. 
environmental factors, P. aeruginosa-induced chronic inflammation), setting conditions for a slower or 
faster evolution [81-82]. 
Gastrointestinal involvement 
Of the several gastrointestinal manifestations in CF, the exocrine pancreas is most profoundly and 
commonly affected (pancreatic insufficient is in 85% of CF patients) [12]. There is a string association 
between specific CFTR alleles and exocrine pancreatic function. A small proportion (2–3%) of patients 
experience gradual transition from pancreatic sufficient to pancreatic insufficient. Preclinical knowledge of 
CFTR genotype (newborn screening) consents an early treatment intervention in patients with two severe 
alleles predictive of pancreatic insufficient. There is emergent evidence that identification of patients 
through newborn screening programs and providing early nutritional support as well as pancreatic enzyme 
supplements in CF children with pancreatic insufficient is important for evolution [13].  
Expression of other less common gastrointestinal complications (MI, liver disease, diabetes) is not 
genotype dependent. However, manifestation of these symptoms is almost exclusively observed in 
patients with pancreatic insufficient and severe CFTR genotypes [83]. 
Other organs 
The sweat glands were examined by measurements of sweat chloride concentration (standard sweet 
testing) in CF patients with different CFTR mutations. The patients were evaluated either according to 
classes of mutations or specific genotypes. Some studies [73] showed that definite mild alleles (R117H; 
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A455E; 3849+10kbC→T) from class IV or V tend to be associated with significantly lower Cl sweat levels 
than those for severe alleles (ΔF508; 621+1G→T; G542X; R553X, etc.). Interestingly, although most 
severe genotypes produce high but similar sweat Cl concentrations, some are significantly associated with 
much higher chloride secretion (i.e., 621+1G→T)[79]. 
Gender-specific expression of the CF phenotype which involves the reproductive tract in men with CF is 
manifested by bilateral absence of the vas deferens or other forms of obstructive azoospermia. The 
majority of males with CF (95%) suffer from this form of infertility [84]. Therefore it appears that the 
male reproductive tract is extremely sensitive to CFTR mutations. Indeed, the clinical spectrum affecting 
the male reproductive tract and associated with defects in the CFTR gene is extending beyond CF in the 
form of isolated congenital bilateral absence of vas deferens (CBAVD). Typically, the genotype in those 
patients consists of at least one very mild mutation uncharacteristic for CF patients. The most interesting 
genotypic feature for these patients is a high prevalence of the RNA splice variant: IVS8-5T (5T) [85-87]. 
The frequency of 5T allele in CBAVD was found to be up to 6 times higher than in general population 
and is present in about 40–50% of patients [88-90]. Additional insights into potential mechanisms 
underlying the differential phenotypic expression in CF and CBAVD patients were gained by analyzing 
CFTR transcripts in nasal epithelium and vas deferens in normal individuals with different T-tract 
genotypes [91].  
Besides CBAVD, a higher than expected frequency of CF mutations/variants has been observed in other 
more common forms of infertility, including obstructive azoospermia and oligospermia [92]. Unlike 
observations in patients with CBAVD, men with obstructive azoospermia rarely harbored two distinct 
CFTR mutations. It has recently been proposed that in absence of a well-defined CFTR mutation, 
frequent polymorphic CFTR variants may predispose to obstructive azoospermia and perhaps other 
CFTR-associated diseases [93-94]. Although the CFTR defect has not been generally implicated in 
spermatogenesis, a recent report [95-97] suggested that the sperm maturation process can be delayed in 
CBAVD patients. Overall, it seems that male reproductive tract is the most sensitive system of all CFTR-
affected tissues to even very minor defects in CFTR function.  
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Diagnosis 
The diagnosis of CF has been based on a positive quantitative sweat test (Cl- ≥ 60 mEq/L) in association 
with 1 or more of the following: typical chronic obstructive lung disease, documented exocrine pancreatic 
insufficiency, or a family history of CF [98].  
The sweat test, using pilocarpine iontophoresis to collect sweat and chemical analysis of its chloride 
content, is the gold standard for the confirmation of CF diagnosis. The procedure requires care and 
accuracy. The collection methods are the Gibson-Cooke procedure and the Macroduct sweat collection 
system. In both, the sweat is stimulated by iontophoresis (3mA of electric current) with pilocarpine, after 
which it is collected with paper filter or gauze (Gibson-Cooke) or in a microbore tube (Wescor). Then, the 
sample is analyzed to determine the concentration of sodium chloride. For reliable results, the minimal 
acceptable sweat volume is 75 mg in the Gibson-Cooke procedure and 15 μL for the Macroduct system 
[98]. Testing may be difficult in first two weeks of life because of low sweat rates, but is recommended any 
time after the first 48 hours of life. Positive results should be confirmed; a negative result should be 
repeated if suspicion of CF remains. The sweat test should always be interpreted in the clinical context. 
The measurement of sodium is useful as a quality control. Highly discordant values indicate errors in the 
collection or analysis. A chloride concentration > 60 mmol/L is consistent with a diagnosis of CF, when 1 
or more other criteria are present. Chloride values between 40 and 60 mmol/L have been reported at all 
ages in cases of typical involvement. False negative test results may occur in young patients with 
hypoproteinemic edema. False positive test may occur when sweat test is performed on pathologic or 
contaminated skin and in case of conditions associated with elevated concentrations of sweet electrolytes 
(untreated adrenal insufficiency, hereditary nephrogenic diabetes insipidus, hypotirodism, 
hypoparathyroidism, fucosidosis, malnutrition) [98].  
The identification of mutations known as the cause of CF in each of the CFTR genes, confirms the 
diagnosis. However, the finding of only one mutation or no mutations in the CFTR gene does not rule 
out a diagnosis of CF [98]. Cases of non-classic CF in which there is no evidence of mutation in the 
CFTR genes have been reported [99].  
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Several commercial laboratories test identifies ≥ 90% individuals who carry two CF mutations. The 
analysis of mutations presents high specificity and low sensitivity for confirming a diagnosis of CF. In fact, 
there are a great number of mutations (over 1000) that are known to cause CF, and the commercial panels 
available for this analysis only study a minority of those mutations [98].  
Most affected newborns can be identified by determination of immunoreative trypsinogen and restricted 
DNA testing on blood spots, associated with confirmatory sweat analysis (95% of sensitivity).  There not 
convincing evidence that early diagnosis and prenatal screening improve pulmonary outcome or survival 
[100]. 
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CF score of severity 
Monitoring of disease progression is evaluated through spirometry and others test of pulmonary function, 
chest radiography and tomography, and clinical evaluations. However, there is some scores to assess 
disease severity in CF, such as Shwachman-Kulczycki (SK) score. 
The SK score, published in 1958, was the first most important score to assess the severity of CF. It was 
developed based on a study which observed 105 patients for 5 years, exposing the need to measure CF 
severity, and to provide a perception of the overall clinical status of the patient [101]. This score is based 
on clinical and radiological evaluation and, despite its subjectivity, it is still widely used. The SK score is 
divided into four classes: general activity; physical examination; state of nutrition; and radiological 
findings. Each class has five possible subscores, according to the degree of severity. The scores of the four 
domains are summed to obtain the final score, from which the impairment of the patient is categorized as 
excellent (86-100), good (71-85), average (56- 70), poor (41-55) or severe (<40) (Table 3). 
Since its publication, many other scoring systems for different aspects of CF have been developed, mainly 
radiological, functional and clinical scores [102]. However, the SK score is still the most used score, 
despite its lack of systematic application and its failure to consider the lung function test. In recent study, 
Stollar demonstrated that the SK score correlated strongly and significantly with FEV1, chest radiography 
and tomography and with the 6-MWT [103]. 
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Table 2: Shwachman-Kulczyki score 
Score Points 
General 
activity 
Physical examination Nutrition 
Radiological 
findings 
Excellent 
(86-100) 
25 
Full normal 
activity.  
Plays, plays ball.  
Goes to school 
regularly. 
Normal. No cough. 
Normal HR and RR. 
Clear lungs.  
Good posture. 
Weight and height 
above the 25th 
percentile. Normal 
stool. Good muscle 
mass and tone. 
Clear lung fields. 
Good 
(71-85) 
  20 
Irritability.  
Tires at end of 
day.  
Good school 
attendance. 
Normal HR and RR at 
rest. Rare cough.  
Clear lungs.  
Minimal emphysema. 
Weight and height 5-
20th percentile. Stool 
slightly abnormal. 
Minimal 
accentuation of 
bronchovascular 
markings. Mild 
emphysema 
Average 
(56-70) 
15 
Needs to rest 
during the day. 
Tires easily after 
exertion.  
Fair school 
attendance. 
Occasional cough, 
sometimes in the 
morning.  
Slightly increased RR.  
Medium emphysema.  
Mild clubbing. 
Weight and height 
above 3rd percentile. 
Abnormal stool, 
poorly formed. 
Abdominal distension. 
Muscle hypotrophy. 
Moderate 
emphysema. 
Increased 
bronchovascular 
markings. 
Poor 
(41-55) 
10 
Dyspnea after 
short walks. 
Rests frequently. 
Frequent, productive 
cough, chest retraction. 
Moderate emphysema. 
May have chest 
deformities.  
Clubbing 2 to 3+. 
Weight and height 
below 3rd percentile. 
Abnormal stool. 
Marked reduction of 
muscle mass. 
Moderate 
emphysema. Areas 
of atelectasis. Areas 
of mild infection. 
Bronchiectasis. 
Severe 
(≤40) 
5 
Orthopnea. 
Bedridden. 
Severe coughing spells. 
Periods of tachypnea and 
tachycardia and extensive 
pulmonary alterations.  
Can show signs of right 
heart failure. Clubbing 3 
to 4+. 
Marked malnutrition 
Abdominal distension. 
Rectal prolapse. 
Extensive 
alterations. 
Obstructive 
phenomena. 
Infection, 
atelectasis, 
bronchiectasis. 
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Treatment of CF 
CF is a systemic disease, so its treatment plan should be comprehensive and linked to close monitoring 
and early intervention. The use of the multidisciplinary approach model to treat CF patients is based on 
the observation that the creation of comprehensive care centers for CF is related to the progressively 
better prognosis of the patients. Despite the great advances in the knowledge regarding CF, the treatment 
of the disease continues to focus on resolving symptoms and correcting organ impairment [104]. 
Initial intervention after diagnosis should be intensive and include baseline assessment, initiation of 
treatment, clearing of lung involvement, and education of patients and parents. The goal of therapy is to 
maintain a stable condition for prolonged periods [98]. 
Pulmonary impairment is the principal cause of morbidity and mortality and an appropriate therapeutic 
approach can slow its progression. The standard therapeutic regimen for the pulmonary manifestations 
includes antibiotic therapy, that is the mainstay of therapy designed to control progression of lung 
infection. Indications to an oral antibiotic therapy include the presence of respiratory tract symptoms and 
identification of pathogenic organism in sputum cultures. The usual course of therapy is greater than two 
weeks, and the dosages for some antibiotics are often 2 to 3 times amount recommended for minor 
infectious. In fact, it is difficult to achieve effective drug levels of many antibiotics in lung secretions and 
CF patients have higher clearance rates [98]. Wherever possible, the choice of antimicrobials drug should 
be guided by in vitro sensitivity testing. For the patients who has progressive or acute respiratory 
infections, intravenous antibiotic therapy is indicated. This treatment is usually initiated in the hospital but 
may be completed at home or within ambulatory bases, with permanent intravenous access. The usual 
course of systemic antibiotic treatment is at least 14 days, and requires two drug therapy, especially in case 
of Pseudomonas infection. The positive culture always must guide the choice of antibiotic treatment [105]. 
Some studies have reported that, in addition to their antimicrobial activity, macrolides have 
immunomodulatory properties in several respiratory diseases. The anti-inflammatory action of macrolides 
was firstly discovered in Japan in the 1980s, when treatment with macrolides significantly increased 
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survival in patients with diffuse panbronchiolitis, a severe chronic lung disease with intense neutrophilic 
inflammation [106]. The most important effects of macrolides are the following: inhibition of pro-
inflammatory cytokine synthesis, inhibition of neutrophil migration to sites of inflammation, inhibition of 
leukocyte degranulation, reduction of eosinophilic inflammation, activation of macrophage phagocytic 
activity and increasing mucociliary transport. Other described actions include reduced goblet cell 
secretion, reduced bronchoconstriction induced by a decreased release of endothelin-1, and inhibition of 
the cholinergic response in the airway smooth muscle [107]. An important study evaluate the effect of 
azithromycin (250 mg/day) vs placebo for 3 months in 60 clinically stable CF patients. Pulmonary 
function levels remained constant in patients with azithromycin, whereas, in patients receiving placebo, 
there was a significant decline in lung function. In addition, patients receiving azithromycin had 
significantly fewer total days of i.v. antibiotic treatment [108]. On the contrary, a chronic use of macrolides 
in CF is significantly related to the emergence of bacterial resistance to this class of antibiotics [109]. 
Aerosol treatment is important to deliver medication and hydrate the lower respiratory tract. Often, anti-
inflammatory drugs (such as corticosteroids or glutatione or N-acetyl-cysteine) and bronchodilators (such 
as albuterol or other β agonists) are employed, especially after chest physical therapy [110]. Human 
recombinant DNase, given as a single daily aerosol dose, improves pulmonary function and decrease rate 
of pulmonary exacerbations, in particular in advanced lung disease after 12 mounts on continuous therapy 
[111]. Hypertonic saline aerosol is reported to improve  mucus clearance and increase FEV1.  Instead, its 
benefits are quite variable and inferior to that documented with recombinant DNase [111]. Finally, aerosol 
delivery of antibiotics offers an option for continuous and home delivery of additional agents. In 
particular, inhaled tobramycin has been studied widely: given twice daily on alternative months, 
Pseudomanas density in sputum decrease after 6 months [112]. It is documented that fewer hospitalization 
are required and pulmonary function can improve by ≥ 10%. Other used inhaled antibiotics such as 
colistin must be used twice a day, but bronchospasm may complicated this aerosolized therapy [113]. 
Airway clearance therapy is a fundamental mainstays of CF management. Chest physical therapy (PT) can 
be particularly useful in this patients because they accumulate secretion in small airways, even before the 
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onset of symptoms. Chest PT include: autogenic drainage; modified autogenic drainage, active cycle of 
breathing, forced expiration, use of oral oscillatory devices, positive expiratory pressure using a mask, high 
frequency thoracic compressions, vest-type mechanical percussors and intrapulmonary percussive 
ventilation [114]. CF patient should be guided in the choice of techniques combinations and should be 
instructed in order to perform correctly these techniques, especially within children. Chest PT is 
recommended from 1 to 4 times a day, guided by severity of lung dysfunction and by patient’s necessity. 
Although immediate improvement of lung function generally cannot be demonstrated after PT, cessation 
of this physical therapy in CF patients results in deterioration of pulmonary function within three weeks 
[115].  
Routine physical activity increases airway clearance and slow the rate of decline in lung function, improves 
cardiovascular performance, increases functional capacity, and improves quality of life [116]. Pulmonary 
rehabilitation programs provide benefits in CF patients, especially in case of low free fat mass [117]. 
Acute and chronic respiratory failure occurs in CF patients after prolonged deterioration of lung function, 
usually as result of a severe viral or other infectious disease. Since a long-standing PaO2 < 50 mmHg 
promotes the development of right side hearth failure, it is recommended low-flow oxygen therapy [98]. 
Some CF patients also present hypoxemia only during exercise or sleeping. Oxygen therapy during 
exercise is indicated if oxygen saturation drops below 90%. Nocturnal oxygen therapy is indicated if the 
oxygen saturation is lower than 90% for 10% or more of total sleep time. Noninvasive mechanical 
ventilation can improve gas exchange in patients with hypercapnia, awaiting a lung transplant [118]. 
Lung transplantation  is the first option for end-stage lung involvement. Due to the suppurative 
complications of CF, most widely used technique is bilateral lung transplant through a sequential bilateral 
surgical procedure using a cadaver donor. The criteria for patient candidacy are: FEV1 < 30% than the 
predicted; severe hypoxemia and/or hypercapnia; progressive functional impairment or increase in the 
duration and frequency of hospital treatment for exacerbations; life-threatening pulmonary complications 
such as hemoptysis. An increased antibiotic resistance of bacterial pathogens and chest infection with B. 
cepacia or non-tuberculous mycobacteria are  negative predictors of outcome. Lung transplantation has 
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demonstrated one-year survival of about 90%, but the five-year survival is only 50%, most probably 
because of the development of chronic rejection as bronchiolitis obliterans [119]. 
There is particular interest in gene therapy, that consists in restoring CFTR function in CF patients 
through insertion of a normal copy of the gene. However, much has been documented from gene therapy 
trials and the airways present many problems to successful gene therapy, more so than many other organs 
[120]. Although we cannot currently supplement mutant CFTR alleles with a normal copy by gene 
therapy, small molecules have been identified that can modulate mutant CFTR cannel such that its 
function may be closer to normality. The first approved CFTR modulator, ivacaftor, is indicated for CF 
patients with a specific mutation. Ivacaftor potentiates the CFTR channel by increasing the probability of 
channel opening, it is associated with improvements in lung function at 2 weeks that were maintained 
through 48 weeks. Substantial improvements can be also observed in the risk of pulmonary exacerbations, 
in patient-reported respiratory symptoms, weight, and in concentration of sweat chloride [121]. 
One prospective treatment is stem-cell therapy. However, knowledge of pulmonary stem cells is quite 
limited, and such researches are still preliminary [122]. 
Pancreatic enzyme therapy in patients with pancreatic insufficiency is associated with increase in the rate 
of fat absorption, reduction in stool frequency and improvement in stool consistency, with weight 
increase. The initial dose is determined by the weight of the patient and level of dietary fat intake. The 
recommended dose is 500 to 1,000 lipase units/kg/meal, which may be increased if clinical signs of 
pancreatic insufficiency (steatorrhea) persist. The maximum daily dose is 2,500 lipase units/kg/meal or 
10,000 lipase units/kg/day, based on reports of the occurrence of DIOS in patients receiving high-dose 
pancreatic enzymes [123]. If steatorrea persists, the concomitant use of proton pump inhibitors or 
histamine H2-receptor inhibitors may be considered to reduce pancreatic enzyme inactivation. Treatment 
aims at a normal intake of fat and other dietary nutrients, and proper development and growth (height and 
weight improvement). Cases in which steatorrhea persists even after administration of high-dose 
pancreatic enzymes should be investigated for other diseases, such as celiac disease, parasitosis, food 
allergy, among others [123]. 
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Because pancreatic insufficiency results in malabsorption of fat-soluble vitamins, it is recommended daily 
vitamins supplementation (A, D, E, K). Additional doses may be required when low serum levels are 
documented or when they became symptomatic [124-126]. 
Many children at diagnosis time have nutritional deficit and an adequate diet plays an important role in the 
clinical course of CF. Malnutrition has many adverse effects on pulmonary functions including decreased 
ventilatory drive, impaired pulmonary muscle function, decreased exercise tolerance, and altered 
pulmonary immune response. Nutritional intervention should begin early, and can decrease deterioration 
of the lung function and have a positive effect on survival. Every CF patient should be regularly evaluated 
in order to monitor the nutritional state and ensure an adequate caloric intake. The recommendation 
includes a high-fat diet, with 35% to 40% of the calories coming from fat (120% to 150% of the estimated 
minimum daily requirement) [127].  
An estimated approximation of the energy needs can be made using the following equation:  
total energy spending =  
basal metabolic rate  
× 1.1 (poor absorption factor) 
× 1.5-1.7(activity factor) 
+ 200 to 400 kcal/day 
Most CF patients have an increased caloric need when infective respiratory exacerbations occur and in 
case of advanced lung disease. These patients can be monitored by determining the 3-day intake and by 
anthropometric evaluation (body mass index, arm circumference, mid-arm muscle circumference, triceps 
skinfold thickness, and weight loss percentage), analysis of body composition (electrical bioimpedance), 
and peripheral muscle strength determination.  
The goal is to maintain a body mass index of 20-25 kg/m2, while a body mass index lower than 19 kg/m2 
indicates significant malnutrition and a more aggressive nutritional intervention  is needed [127]. For all 
age categories, a special attention must be given if stunting is evident, defined as ht/age of <90% or 
height centile <0.4th (Table 3). 
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In end-stage phase, weight stabilization requires nocturnal feeding via nasogatric tube or percutaneous 
enterostomy or short-term intravenous supplementation [128].  
 
 
Table 3: three class of severity in nutritional status. 
Nutritional 
Status 
<5 years 5-18 years > 18 years Intervention 
Normal 
nutritional state 
Wt/ht 90-110% Wt/ht 90-110% BMI 19-25 
kg/m2 
and/or no recent 
weight loss 
Preventative 
counselling 
Light malnutrition Wt/ht 85-89% or 
weight loss over 4 
months or plateau in 
weight over 6 months 
Wt/ht 85-89% or 
weight loss over 6 
months or plateau in 
weight over 6 months 
BMI <19 kg/m2 
or 5% weight 
loss over more 
than 2 months 
Consider 
supplements 
Severe 
malnutrition 
Supplements tried and 
either wt/ht <85% or 
weight falling 2 centile 
positions 
Supplements tried and 
either- wt/ht <85% 
or weight falling 2 
centile positions 
Supplements 
tried 
and either- BMI 
<19 kg/m2 or 
>5% weight 
loss over more 
than 2 months 
Aggressive 
nutritional 
support 
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Docosahexaenoic Acid (DHA) 
Fat is an essential component of the diet [129]. On a fat-free diet, rats do not grow or reproduce. Essential 
fatty acids include linoleic acid and its omega-6 derivative, arachidonic acid (AA). More recently, the vital 
role of alpha-linolenic acid and its omega-3 derivative, docosahexaenoic acid, has been recognized [129]. 
Omega-3 (ω-3) fatty acids are polyunsaturated fatty acids (PUFAs) and essential components for the 
growth of higher eukaryotes [130]. Nutritionally, eicosapentaenoic acid (EPA, 20:5) and docosahexaenoic 
acid (DHA, 22:6) are the most important fatty acids belonging to this group of bioactive compounds. 
DHA can be synthesized from alpha-linolenic acid or obtained directly from maternal milk or fish oil. Its 
structure is a carboxylic acid with a 22-carbon chain and six cis double bonds; the first double bond is 
located at the third carbon from the omega end (Fig. 1). Its trivial name is cervonic acid, its systematic 
name is all-cis-docosa-4,7,10,13,16,19-hexa-enoic acid, and its shorthand name is 22:6(n-3) in the 
nomenclature of fatty acids. DHA is a primary structural component of the human brain, cerebral cortex, 
skin, sperm, testicles and retina. DHA is the most abundant omega-3 fatty acid in the brain, in sperm and 
retina. DHA comprises 40% of the polyunsaturated fatty acids (PUFAs) in the brain and 60% of the 
PUFAs in the retina [131]. Fifty percent of the weight of a neuron's plasma membrane is composed of 
DHA. In the brain, DHA modulates the carrier-mediated transport of choline, glycine, and taurine, the 
function of delayed rectifier potassium channels, and the response of rhodopsin contained in the synaptic 
vesicles, among many other functions. 
Cold-water oceanic fish oils are rich in DHA. Most of the DHA in fish and multi-cellular organisms with 
access to cold-water oceanic foods originates from photosynthetic and heterotrophic microalgae, and 
becomes increasingly concentrated in organisms the further they are up the food chain [131]. Many marine 
microalgal strains have oil contents of between 10–50% and produce a high percentage of total lipids (up 
to 30–70% of dry weight) [130]. The accumulation of fatty acids is closely linked to microalgal growth 
stages, functioning as an energy stockpile during unfavorable conditions or cell division. Omega-3 is 
accumulated due to its high energy content, as well as the good flow properties crucial for cellular 
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functions. DHA is also commercially manufactured from microalgae; Crypthecodinium cohnii and 
another of the genus Schizochytrium [132-133].  
DHA is essential for the growth and functional development of the brain in infants. DHA is also required 
for maintenance of normal brain function in adults. DHA deficiencies are associated with fetal alcohol 
syndrome, attention deficit hyperactivity disorder, CF, phenylketonuria, unipolar depression, aggressive 
hostility, and adrenoleukodystrophy. Epidemiological studies have shown that omega-3 fatty acid 
consumption reduces Alzheimer disease risk and DHA modifies the expression of Alzheimer-like brain 
pathology in mouse models [134-135]. Several studies have also shown a strong correlation between fish 
consumption and reduction in sudden death from myocardial infarction. The reduction is approximately 
50% with 200 mg day-1 of DHA from fish [137].  
Moreover, children who ate fresh, oily fish more than once per week had a significantly reduced risk of 
present asthma. No other food groups were associated with any risk difference for asthma [140]. In 
another study, 39 asthmatic children were supplemented with omega-3 or omega-6 fatty acids. Significant 
differences were seen in plasma phospholipid fatty acids and TNF-a production was lower than baseline 
in the omega-3 group. No significant differences were found in clinical outcome measures in this study 
[138]. Broughton studied asthmatic patients that sequentially given a diet with a 10:1 or 2:1 ratio of 
omega-6 to omega-3 PUFA for 1 month each. The patients were then stressed with methacholine 
inhalation. Methacholine-induced respiratory distress increased with low omega-3 PUFA ingestion [140]. 
In fact, leukotriene synthesis from AA is involved in the asthma process through vasoconstriction and 
mucus secretion and it is inhibited by long-chain omega-3 PUFA. 
Humans originally consumed a diet rich in the omega-3 fatty acids and poor in saturated fatty acids 
because wild and free-range food animals have much higher contents of omega-3 fatty acids than the 
present-day commercial livestock. The dietary supply of fatty acids previously contained a 1:1 ratio of 
omega-6 to omega-3 polyunsaturated fatty acids. The present ratio in the US is greater than 10:1, causing a 
deficiency of the omega-3 fatty acids. The excess of omega-6 fatty acids stimulates the formation of AA, 
the fatty acid precursor of prostaglandins and other eicosanoids that are involved in inflammation [140]. 
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Figure 1: DHA’s structure 
DHA in CF 
Several reports have indicated the presence of specific fatty acid alterations in CF patients. When this 
phenomenon was first noted more than 40 years ago, the primary abnormalities identified were decreased 
linoleic acid (LA) levels in different organs and tissues. Since pancreatic insufficiency is present in more 
than 80 percent of CF patients, these abnormalities have been initially presumed to be secondary to fat 
malabsorption and therefore not a primary abnormality due to CFTR mutations [141]. 
In later 30 years, some studies have given support to the theory that the essential fatty acid abnormalities 
in patients with CF may have a fundamental role in the symptoms and progression of the disease [142]. It 
is well documented that in newborn with CF, identified by neonatal screening or by MI manifestations, 
low LA concentrations are present at birth and are more pronounced in infants who present with MI 
[143]. Abnormal metabolism of fatty acids has been described by several groups, and increased release of 
AA, the most important metabolic product of LA, has been documented in vitro systems [144]. Later 
studies demonstrated additional significant alterations in the levels of fatty acid in the blood and tissues of 
CF patients, most notably decreased levels of DHA [145]. 
AA is the substrate for inflammatory metabolites, such as prostaglandin E2 (PGE2), thromboxane A2 
(TXA2), leukotriene B4 (LTB4), and the cysteinyl leukotrienes. In the process of the transformation of 
different groups of longchain fatty acids, an increase of one group of fatty acids, those of the omega-3 
series, has been shown to slow the transformation of omega-6 fatty acids. There is both an increase in AA 
and a marked increase of the prostanoids, which might contribute to the inflammation that characterizes 
CF [147]. Since DHA, in an in vitro system, has been shown to inhibit the synthesis of prostanoids but 
not of leukotrienes, a decrease in DHA might contribute to the increased prostanoid synthesis in CF 
[148]. 
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Over the last 10 years, several lipid mediators DHA-derived, such as resolvins and protectins, arising from 
the coordinated activity of 5-, 15-, and other lipoxygenases, have been identified as important factors in 
the resolution phase of the inflammatory reaction, raising considerable interest on the potential deficit of 
these lipid mediators in chronic inflammatory conditions. These new compounds possess potent actions 
in controlling the resolution of inflammatory exudates: the term resolvins, resolution phase interaction 
products, was introduced to signify that the new structures are endogenous, local-acting mediators 
possessing potent anti-inflammatory and immunoregulatory properties. At the cellular level, these include 
reducing neutrophil infiltration and regulating the cytokine-chemokine axis and reactive oxygen species, as 
well as lowering the magnitude of the inflammatory response [148]. The protectin family, neuro-protectin 
when generated in the neural tissue [148], was named after the potent anti-inflammatory as well as 
protective actions demonstrated in animal models of stroke and Alzheimer’s disease [149]. Both families 
of lipid mediators are potent local-acting agonists of endogenous anti-inflammation that promote 
resolution. Protectin D1 and its immediate precursor 17S-hydroxy-docosahexaenoic acid were identified 
in exhaled breath condensates from healthy subjects, and significantly lower concentrations were detected 
in exhaled breath condensates from subjects with asthma exacerbations [150], providing evidence for 
endogenous PD1 as a pivotal counter-regulatory signal in airway inflammation and pointing to new 
therapeutic strategies for modulating inflammation in the lung. 
These data, along with the observation that mice with a targeted deletion of the CFTR gene have an 
abnormal ratio AA/DHA in pancreatic tissue, have led to the speculation that abnormalities in the 
metabolism of AA and DHA may be important in evolution of CF.  Freedman et al. have shown that diet 
with high doses of DHA in CF–knockout mice corrects the fatty acid abnormality, reverses the histologic 
changes in the pancreas and ileum, and decreases neutrophil and the eicosanoids levels in mice with 
Pseudomonas lipopolysaccharide– induced pneumonia [151]. These authors also demonstrated an increased 
ratio AA/DHA in nasal and rectal epithelium, tissues that express CFTR, in patients with CF and 
pancreatic sufficiency, who have normal assimilation of micronutrients and macronutrients. It is important 
to note that the ratio in nasal mucosal scrapings from obligate heterozygotes was intermediate between 
values in subjects with CF and healthy control subjects [152]. 
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Moreover, recently Tetaert et al demonstrated that lung infection by P. aeruginosa induced a disregulation 
of the large mucins (such as Muc5b and Muc4). These modifications of mucin expression are modified by 
dietary long-chain fatty acids with a beneficial suppressive effect of PUFAs confirming [153]. This 
strongly supports that malnutrition can compromise lung defenses against P. aeruginosa colonization. 
Therefore, it seems rational to try to normalize plasma abnormal levels of essential fatty in CF patients. 
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Aims of the study 
DHA and his mediators are important factors in the resolution phase of the inflammatory reaction, raising 
considerable interest on the deficit of these lipid metabolites in FC and its systemic chronic inflammatory 
condition. We hypothesized that mediators derived-DHA could be significantly lower in airway of CF 
patients, as compared to another neutrophilic inflammatory disease, such as COPD, and that this 
condition could be reversible by DHA oral supplementation.  
The aim of the study was, therefore, to determine the levels of the AA and DHA-metabolites in sputum 
of adults with CF subjects, as compared to patients with COPD; to ascertain whether or not DHA 
supplementation may affect the fatty acid pattern in CF subjects. 
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4. Materials and Methods 
We studied 15 CF subjects and 10 COPD Gold stage 2-3 patients (not age-matched). CF patients (age 
range 20 to 40 years) were recruited at the Cystic Fibrosis Unit of Parma Hospital and the control group 
of COPD patients were recruited at the University Hospitals of Modena-Reggio Emilia and Parma. All 
patients with CF were diagnosed by evidence of CFTR dysfunction (elevated sweat test) and/or 
identification of two pathological CFTR mutations (INNO- LiPA CFTR19®). The inclusion criteria were 
as following: genotype ΔF508 homozigous, mild/moderate pulmonary disease (FEV1 ≥40% predicted 
value), and pancreatic insufficiency. All patients was clinically stable and following standard CF therapy.  
All subjects recruited performed at baseline: nutritional status evaluation, severity score evaluation (SK 
score), spirometry, exhaled NO measurement, SI, EBC, and their blood sample were drawn to evaluate 
their fatty acid profile (first phase). In second phase, CF patients performed all evaluations after ten weeks 
with DHA-supplementation and after ten weeks without DHA-supplementation. 
Nutritional status was assessed and expressed as BMI (kg/m2). 
The pulmonary function was measured by body pletismograph (B3Box Biomedin, Padua, Italy) and 
oxygen saturation (SatO2) was measured by pulse oxymetry  (Nellcor N-395).  
FeNO was measured according to the ATS/ERS guidelines [154] using a stationary chemiluminescence 
analyzer (NIOX, Aerocrine AB, Solna, Sweden), which has been approved by the U.S.A. Food and Drug 
Administration for use in asthma management [155]. FeNO measurement was performed at the same 
time of day to allow a possible circadian rhythm effect. In detail, FeNO measurement was performed 
asking the subjects, who was seated in the upright position without a nose clip, to inhale nitric oxide-free 
air through a filter connected to the device deeply to total lung capacity and then to exhale for 10s at a 
constant pressure guided by a visual cue to stabilize flow rate. All tests were performed at an exhalation 
pressure of 10-20 cm H2O, to maintain a fixed flow-rate of 50 ml/s. Measurements were repeated after a 
brief rest period until two acceptable values (±2.5 p.p.b. for measurements <50 p.p.b. and ±5% for 
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measurements ≥50 p.p.b.) were performed (maximum six attemps). The mean of two adequate values for 
each subject was recorded for analysis. 
SI was performed in accordance with the European Respiratory Society task force [156, 157]. FEV1 and 
FVC were measured at baseline and after inhalation of salbutamol (200 µg by metered dose inhalers). 
After that, subjects were asked to rinse their mouth. Subjects inhaled sterile hypertonic saline (NaCl, 3%, 
prepared by the hospital chemist) nebulized with an ultrasonic device (Heyer Orion 1, BAD EMS; mean 
volume output: 2.40 ml/min) for four cycles of 5 minutes each. After each cycle and when needed they 
were asked to rinse their mouth and cough in to a plastic container. Three flow volume curves were 
performed before and after each inhalation and the best FEV1 was recorded. Induction of sputum was 
stopped if FEV1 value fell by at least 15% from baseline or if troublesome symptoms occurred. The 
collected sputum samples were processed [158]. The volume of the sputum sample was measured and an 
equal volume of dithiotreitol 0.1% was added and incubated at 37°C for 30 min. Ten microlitres of the 
homogenised sample was used to determine the total cell count and results were expressed as number of 
cells/ml. The remaining sputum was centrifuged at 2000 rpm for a 5 min period. The supernatant was 
aspirated, and cell pellets will be re-suspended in PBS (2000 rpm for 10 min), cytocentrifuged at 600 rpm 
for 10 min and stained with May-Grunwald-Giemsa. Only samples with less than 20% squamous cell 
contamination, to exclude salivary contamination, and more than 50% viable cells was considered suitable. 
Cell count was performed on at least two slides for an overall differential count of 800 nucleated 
nonsquamous cells and was reported as the relative numbers of eosinophils, neutrophils, macrophages, 
lymphocytes and bronchial epithelial cells, expressed as a percentage. The percentage of squamous cells 
was reported separately. 
EBC is a non-invasive method [159] for studying the composition of airway lining fluid and provides 
biological insight into the pathogenesis of respiratory disorders. Based on the currently available evidence 
and the consensus of the expert panel for EBC collection, EBC was collected by using Cosmed Rtube 
(Cosmed, Milan, Italy). The subject breathed trough a mouthpiece and two-way non rebreathing valve. 
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They was asked to breathe at a normal frequency and tidal volume, for a period of 10 min. Condensate, at 
least 1ml, was collected, transferred to Eppendorf tubes and immediately stored at – 80°C.  
Samples were kept at -80 °C until transferred to the Milano unit for analysis. After thawing, EBC and 
sputum supernatant samples (1 ml) were added with stable isotope labeled internal standards ([d4]LTB4, 
[d4]PGE2, [d8]5-HETE, and [d5]LXA4 2.5 ng each), centrifuged to remove particulate, acidified with 
acetic acid (final concentration 0.01%) and extracted using preconditioned polymeric solid phase 
extraction cartridges (Strata-X, 33 µm Polymeric Reversed Phase, Phenomenex, Torrance, CA). After 
washing with ultrapure water, DHA- and arachidonic acid-derived metabolites were eluted using 
methanol/water, 90/10, v/v (0,5 mL), and the eluate taken to dryness using a rotary vacuum evaporator 
(SpeedVac, Thermo Scientific, Waltham, MA). Upon reconstitution in 40 µL HPLC solvent A (8.3 mM 
acetic acid buffer to pH 5.7 with ammonium hydroxide) plus 20 µL of HPLC solvent B 
(acetonitrile/methanol, 65:35, v/v), an aliquot of each sample (20 µL) was injected onto a C18 HPLC 
column (Ascentis 150 x 2 mm, 3 µm, Supelco, Bellefonte, PA) and eluted at the rate of 400 µL/min with a 
linear gradient from 45% solvent B, which was increased to 75% in 12 min, to 98% in 2 min, then held for 
11 min before re-equilibration at 45% B for 10 min. The HPLC effluent was directly infused into an triple 
quadrupole mass spectrometer (6460, Agilent) equipped with electrospray ion source for mass 
spectrometric analysis in the negative ion mode using multiple reaction monitoring (MRM) for the specific 
m/z transitions: 343-281 for 17(S)OH-DHA (the precursor of both resolvins and protectins), 359-206 for 
protectin D1 and for its isomer I 10(S),17(S)-DiHydroxyDocosahexaenoic acid, 375-141 for resolvin D1, 
335-195 for LTB4, 319-219 for 15-HETE (a marker of 15-lipoxygenase activity), 351-271 for PGE2, 327-
116 for [d8]5-HETE, 339-197 for [d4]LTB4, 359-275 for [d4]PGE2 and 356-222 for [d5]LXA4. (Pioselli 
et al, 2010). Quantitation was performed using isotope dilution of the internal standards and data analyzed 
using MassHunter software. Standard curves were obtained using synthetic LTB4, PGE2, resolvin D1 and 
10(S),17(S)-DiHydroxyDocosaHexaEnoic acid (isomer I of protectin D1), 15-HETE and 17OH-DHA 
(Cayman Chem, Ann Arbor, MI). The peak-area ratios of every compound to the relevant deuterated 
internal standard was calculated and plotted against the amount of the synthetic standards. Calibration 
lines were calculated by the least squares linear regression method and the correlation coefficient r2 was 
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alway better than 0.99. To calculate the concentration of any given analyte the peak-area ratio to the 
relevant internal standard was calculated and read off the corresponding calibration line. Detection limit 
varied between 1 pg to 25 pg depending on the analyte. Optimization of declustering potential, collision 
energy and CXP, was carried out for each metabolite directly injecting 1-5 ng of synthetic standard using 
the same eluent used for the analysis. 
For the determination of Fatty Acid composition of erythocytes membrane phosholipids, blood samples 
were collected in 10% sodium heparin and centrifuged at 200 g for 18 min. The lower fraction was 
additionally centrifuged at 800g for 18 min and the pellet washed twice with phosphate buffer containing 
0.1M NaH2PO4 (5:1 v/v). Cells were lysed with water, followed by spotting on preconditioned absorbing 
strips (Rise et al, 2010). Fatty acid methyl esters were prepared by transesterification with 3N methanolic 
HCl (Supelco). Methyl esters were analyzed on a GC 1000 (Dani, Monza, Italy) gas chromatograph, 
equipped with a flame ionization detector, using an Omegawax 320 column (Supelco). Peaks were 
identified by using pure reference compounds. The fatty acids will be quantified by referring to an internal 
standard (19:0) [160]. 
The results of exhaled NO concentrations, total and differential cell counts in sputum samples, respiratory 
function parameters, fatty acid profile and pro- and anti-inflammatory mediators concentrations in EBC 
and sputum were analyzed for potential correlations within each group of subjects.  
Statistical analysis 
Data are reported as mean ± standard deviation (SD), unless otherwise specified. The distribution of 
variables was assessed by means of Kolmogorov-Smirnov Goodness-of-Fit test. Comparisons for each 
parameter among the different groups were carried out, and the statistically significant difference was set 
at  p <0.05. 
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5. Results 
We studied fifteen patients (9 female) affected by FC, aged between 15 and 40. Table 4 shows the 
demographic data, SK score, pulmonary function and nutritional status for patients in this study. 
Table 4: demographic, anthropometric and functional characteristics of CF patients at baseline 
No Patients BMI (kg/m2) Age  (years) Gender 
(F/M) 
FEV1 (%) FEV1/FVC  
(%) 
SK 
SCORE 
1 B.A 20 32 F 46 62 80 
2 C.D. 22.3 36 F 46 67 50 
3 C.E. 20.4 27 F 81 87 75 
4 F.G. 21.7 37 M 85 73 75 
5 I.M. 24 40 M 71 78 85 
6 L.L. 20 26 M 65 87 65 
7 M.L. 20.4 23 F 53 58 80 
8 M.E. 22.2 31 M 99 93 75 
9 P.S. 19.2 29 F 28 52 70 
10 P.A. 19 30 F 68 83 60 
11 R.S. 19.9 32 F 74 67 75 
12 R.A. 22.5 23 M 72 89 75 
13 V.M. 19.8 15 F 93 86 55 
14 V.L. 20 29 F 72 80 70 
15 Z.C. 21.4 29 M 94 98 60 
Mean 20.9 29.3  69.8 77.3 70 
SD ± 1.4 ± 6.2  ± 19.9 ± 13.6 ± 10 
Ratio (F/M)   9/6    
 
All 15 CF patients completed first phase. 4 out of 15 subjects (3 female) had recruitment of chronic 
inflammatory condition and performed complete evaluations of nutritional status, functional status and 
EBC/SI analysis after two weeks of systemic antibiotic therapy. 9 out of 15 patients (5 female) were stable 
and completed second phase after ten weeks with DHA-supplementation and after ten weeks without 
DHA-supplementation. 
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Characteristic inflammatory status of CF patients were neutophilic and table 5 shows cytological analysis 
on SI at baseline.  
Table 5: cytological analysis on SI of CF patients at baseline 
No Patients Epithelial cells  
(%) 
Macrophages  
(%) 
Neutrophils  
(%) 
Lymphocyte     
(%) 
Eosinophil 
(%) 
1 B.A 0 13 84 1.5 1.5 
2 C.D. 0 16 79 1 2 
3 C.E. 1 14 83 2 1 
4 F.G. 2 31 67 0 0 
5 I.M. 1.5 11 85 2.5 0 
6 L.L. 0 16 83 0.5 0.7 
7 M.L. 0.4 15 83 0.4 2 
8 M.E. 0.3 11.3 86.6 0.2 1.5 
9 P.S. 0 11 84 2 3 
10 P.A. 1 35 60 0.5 3.5 
11 R.S. 1 17 79 3 0 
12 R.A. 0 19 77 3 1 
13 V.M. 2 30 63 4 1 
14 V.L. 3 13 81 0 3 
15 Z.C. 1 19 77 2 1 
Mean 0.7 16.2 80.2 1.6 1.3 
SD ± 0.9 ± 7.3 ± 8.1 ± 1.2 ± 1.61 
 
 
Direct comparison of CF subjects with COPD subjects clearly showed markedly increased concentrations 
of LTB4, PGE2 and 15-HETE in CF subjects. Strikingly, the concentrations of the DHA derived 17OH-
DHA were very similar in the two groups, showing that a rather large unbalance of AA-derived 
inflammatory mediators over the DHA-derived metabolites was occurring in CF patients (Fig. 2). 
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Figure 2: concentrations of LTB4, PGE2, 15-HETE and 17OH-DHA in CF subjects and in COPD subjects 
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The sputum concentrations of 5- and 15-lipoxygenase metabolites LTB4 and 15-HETE showed a 
decreasing trend at the end of the DHA supplementation, a decrease that was statistically significant for 
15-HETE (Fig. 3A and 3C). Decreased concentrations, when compared to basal values, were also 
observed at the end of the washout period, although the difference did not reach statistical significance. A 
similar trend (although less pronounced) was observed for the cyclooxygenase product PGE2 (Fig. 3B). 
On the contrary, and in agreement with the observed enrichment of membrane phospholipids in DHA, 
17OH-DHA showed a trend toward an increase in concentrations at the end of the DHA 
supplementation (Fig. 3D), resulting in a significant correction of the unbalance between AA and DHA-
derived lipid mediators observed under basal conditions. 
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Figure 3: concentrations of LTB4, PGE2, 15-HETE and 17OH-DHA in CF subjects after ten weeks of 
DHA supplementation 
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Table 6 shows the mean concentrations (± SD) of LTB4, PGE2, 15-HETE, 17OH-DHA and ratio 15-
HETE/17OH-DHA in CF subjects after 10 weeks with DHA supplementation  and after 10 weeks 
without DHA supplementation. 
 
 
Table 6: mean concentrations (± SD) of LTB4, PGE2, 15-HETE, 17OH-DHA and ratio 15-HETE/17OH-
DHA in CF patients at visit 1, at visit 2 and at visit 3. 
 LTB4  PGE2  15-HETE  17-OH-DHA RATIO  
15-HETE/ 
17-OH-DHA 
V1 
(baseline) 
16,18 ± 22,57 19,74 ± 31,05 35,63 ± 16,54 7,18 ± 4,68 6,70 ± 5,99 
V2 
(after diet  
with DHA) 
6,58 ± 7,55 16,31 ± 32,61 19,03 ± 12,95 11,98 ± 15,94 2,70 ± 1,65 
V3 
(after diet  
without DHA) 
8,80 ± 8,91 12,23 ± 18,06 30,08 ± 21,03 11,52 ± 9,76 11,52 ± 9,76 
 
 
 
 
Analysis of fatty acid composition in the subgroup (8 subjects) that received 10 weeks of DHA 
supplementation showed a significant increase in the DHA/AA ratio, as well as in the n-3 highly 
unsaturated fatty acid (HUFA) index, representing the percentage of n-3 fatty acids over the total amount 
of HUFA present in red blood cells phospholipids (Fig 4). 
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Figure 4: DHA/AA ratio and HUFA index after supplementation 
 
 
 
 
Indeed, DHA supplementation in CF subjects significantly decreased the ratio between the concentrations 
of 15-HETE and 17OH-DHA to values that were not different from that observed in COPD subjects 
(Fig. 5). 
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Figure 5: ratio between the concentrations of 15-HETE and 17OH-DHA in CF subjects, before and after 
DHA supplementation, and COPD subjects 
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6. Discussion 
The essential fatty acids, in particular omega-3, are precursors to important lipid mediators, that are pro-
resolving and anti-inflammatory. These pro-resolving lipid mediators (including resolvins and protectins) 
appear to play a physiological role in ending inflammation [161]. They stimulate the uptake of apoptotic 
PMNs [162] and activate endogenous antimicrobial defense mechanisms [163] as well as clearance on 
mucosal surfaces [164].  
In fact, the acute inflammatory response is generally a self-limited mechanism, initiated by PNM in 
response to damage or infection. Excessive inflammatory responses can lead to chronic disorders, owing 
to PMN-derived pro-inflammatory mediators, including LTB4 and PGE2. Within inflammatory exudates, 
neutrophils can change phenotypes to generate anti-inflammatory mediators, derived from essential fatty 
acids, to promote a resolution of the inflammatory battle and to return homeostatic health state [165]. 
These protective mediators include the EPA-derived resolvin E-series, and DHA-derived resolvin-D 
series and protectins. Resolvins are generated in human whole blood with enzymatic conversion of DHA 
to 17-hydroxydocosahexaenoic acid (17OH-DHA). Generation of these compounds is significantly 
increased in the presence of aspirin [166,167]. These discoveries reinforce the evidence that the resolution 
of acute inflammation is not passive, but an dynamically regulated response. Of interest, the production of 
protectins and resolvins, when administered in vivo can accelerate this process and the return to tissue 
homeostasis [168]. At the cellular level, these include reducing neutrophil infiltration and regulating the 
cytokine-chemokine axis and reactive oxygen species, as well as lowering the magnitude of the 
inflammatory response [148]. 
Some authors studied an oxygen-induced retinopathy murine model and they compared the effects of 
omega-3 vs omega-6 PUFAs, on retinal angiogenesis in wild-type mice and in mice that overexpressing 
the fat-1 gene, to determine whether EPA, DHA, and AA regulate retinal vaso-obliteration and 
neovascularization in vivo [169]. Fat-1 gene converts omega-6 PUFA into omega-3, resulting in elevated 
tissue levels of omega-3 PUFA within the fat-1 overexpressing mice. A protective outcome against 
uncontrolled angiogenesis, it was found in the retina when there was a inferior ratio of omega-6/omega-3 
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PUFA. Wild-type mice lacking the fat-1 transgene had more diffuse vaso-obliteration and more severe 
retinal neovascularization, if compared with fat-1 mice [170]. Of interest, in mice fed omega-3 PUFA, 
there were markers of biosynthesis of neuroprotectin D1 and resolvina E1 in the retinal tissues. In wild-
type mice, a supplementation of resolvina D1, resolvina E1 or neuroprotectine D1 gave protection from 
vaso-obliteration and neo-angiogenesis. Resolvina E1 is also protective in periodontal disease in rabbits, 
where it appears to stimulate regeneration [171,172]. A recent study showed that increased intake of 
omega-3 PUFAs alleviates obesity-induced insulin resistance and advanced hepatic steatosis in obese mice 
[173]. These beneficial effects were associated with up-regulation of genes involved in insulin sensitivity, 
glucose transport, and insulin receptor signaling in adipose tissue and liver.  
Little is known about the role of resolvins and protectines in lung disease, but as resolvins have been 
shown to exercise anti-inflammatory effects in models of peritonitis and renal ischaemia–perfusion injury 
[174,175], it is likely that resolvins would also be lung protective and promote the resolution of airway 
damage and inflammation. Grau-Carmona et al demonstrated that, in septic patients with acute lung injury 
or ARDS, an enteric feeding of supplements enriched with omega-3 PUFA improves clinical outcomes, 
including time to liberation from mechanical ventilation and discharge from the intensive care unit [176]. 
Moreover, protectin-D1 and its immediate precursor 17OH-DHA, have been identified in EBC from 
healthy subjects, and significantly lower concentrations were detected in EBC from subjects with asthma 
exacerbations [177]. 
The essential fatty acids and their proportion have been documented to have also a remarkable effect on 
membrane receptor function, transmembrane signaling mechanisms, phospholipase activation, calcium 
release, ion channels, and gene expression. Disturbances of this complex interactive system can have 
central importance for cell function. Actually, the molecular mechanism by which CFTR regulates fatty 
acid metabolism is unknown, but several studies show that the decreased DHA levels may be important in 
the excessive chronic inflammatory response in CF [145]. Freedman et al. have previously shown that oral 
supplementation of high doses of DHA to CF–mice corrects the fatty acid abnormality and decreases 
neutrophil levels in mice with pseudomonas lipopolysaccharide–induced pneumonia [151]. 
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It is important to studying essential fatty acids and determining whether correction of DHA defect 
represents a treatment for CF. Cutting-edge analytical methods in mass spectrometry were applied to the 
analysis of AA and DHA-derived lipid mediators in EBC and sputum samples, under the hypothesis that 
the known deficit in DHA correlate with a decreased concentrations of DHA-derived anti-inflammatory 
and pro-resolution mediators within the airways of CF subjects. The analysis EBC yielded a very limited 
number of samples in which all the metabolites of interest could be detected. On the contrary almost all 
the sputum samples resulted in significant amounts of several lipid mediators, such as LTB4, PGE2 and 
15-HETE as well as the precursor of protectins and resolvins 17OH-DHA. 
In agreement with previous studies [141, 167], we observed a quite significant unbalance between AA-
derived pro-inflammatory mediators and the precursor of protectins and resolvins 17OH-DHA in the 
airways of CF subjects. DHA supplementation caused an overall decrease in the concentrations of pro-
inflammatory mediators such as 15-HETE and LTB4, suggesting that the decreased concentrations of 
DHA observed in CF subjects could indeed cause a lack of proresolving lipid mediators. Moreover, DHA 
supplementation strikingly corrected the observed unbalance between AA- and DHA-derived 
compounds, providing evidence supporting a potential anti-inflammatory activity of n-3 PUFA 
supplementation in CF subjects.  
For the first time, this study had compared these lipid mediators in FC patients to COPD patients, 
another prevalently neutrophilic chronic inflammatory condition, and had demonstrated that a DHA diet 
was able to correct fatty acid impaired pattern. We acknowledge that the small sample size of a pilot study 
can represent an limitation. Moreover, it is possible that a longer DHA supplementation can reveal some 
important clinical and functional correlation with these mediators. 
The results of this pilot study open up a novel therapeutic approach based on the oral treatment with 
these endogenous anti-inflammatory molecules. In future, it is important to study long-term DHA-
supplementation in more numerous CF population, as compared to COPD patients, healthy smokers and 
patients with asthma. In more wide CF population, it will be possible to correlate molecular data to clinical 
and functional data. 
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